Mark Minichiello
About Mark Minichiello
Mark Minichiello is the Global Talent Acquisition Lead, Commercialization at Bristol Myers Squibb, with extensive experience in talent acquisition and HR operations across multiple companies.
Current Role at Bristol Myers Squibb
Mark Minichiello is the Global Talent Acquisition Lead for Commercialization at Bristol Myers Squibb. In this role, he is responsible for implementing a global talent acquisition strategy that has significantly reduced the time-to-hire. He specializes in volume recruiting and managing high-volume hiring processes effectively. Additionally, he leads efforts to improve recruitment efficiency across multiple locations by developing and guiding remote staffing initiatives.
Previous Experience at bluebird bio
From 2018 to 2020, Mark Minichiello served as the Vice President of Talent Acquisition & HR Operations at bluebird bio in the Greater Boston Area. During his tenure, he focused on enhancing recruitment practices and streamlining HR operations to support the company’s growth. His role also involved executive interaction and aligning talent acquisition strategies with business goals.
Everbridge Recruitment Chief
Between 2015 and 2018, Mark Minichiello held the position of Chief Recruiting Officer at Everbridge. He was responsible for overseeing the company's recruitment operations, ensuring efficient hiring processes, and managing recruitment strategies to meet organizational needs.
Role at Nuance Communications
Mark Minichiello worked as the Sr. Director of Global Talent Acquisition at Nuance Communications from 2012 to 2015 in Burlington, MA. In this capacity, he led global recruitment efforts, handled high-volume hiring processes, and contributed to talent acquisition strategies aligning with business objectives.
Involvement in Pre-Approval Access Programs
At Bristol Myers Squibb, Mark Minichiello plays a critical role in the Pre-Approval Access program, ensuring that investigational medicines are provided fairly and equitably to eligible patients. He works closely with patients' physicians to determine the appropriateness of providing these medicines and ensures that doing so does not compromise the scientific validity of broader development programs or regulatory filings. His work involves careful consideration of patient safety and potential benefits, aiming to balance individual needs with larger regulatory goals.